España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Viatris
VTRS
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$12.52
0.39
3.22%
At close: -
$12.40
-0.12
-0.96%
After Hours: Dec 20, 6:29 PM EDT
Get Report
Comment
Viatris (VTRS) Forecast
News
Earnings
Viatris (VTRS) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Viatris (NASDAQ:VTRS) Stock
Viatris Stock (NASDAQ: VTRS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, December 18, 2024
Viatris Announces Publication Of Phase 2b CAR...
Benzinga Newsdesk
Friday, December 06, 2024
Piper Sandler Reiterates Neutral on Viatris, ...
Benzinga Newsdesk
Thursday, November 07, 2024
Wall Street Hits Record Highs After Powell's Speech, Lifts Magnificent 7 Stocks To $17 Trillion In Historic Trading
Piero Cingari
Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown
Vandana Singh
Viatris shares are trading higher after the c...
Benzinga Newsdesk
Viatris Lowers FY24 Adj EPS Guidance from $2....
Benzinga Newsdesk
Viatris Q3 2024 Adj. EPS $0.75 Beats $0.68 Es...
Benzinga Newsdesk
Saturday, November 02, 2024
These 10 Stocks Were S&P 500's Worst Performers In Biden's First Year: Could Trend Continue If Harris Wins 2024 Election?
Chris Katje
Friday, November 01, 2024
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
Vandana Singh
Wednesday, October 16, 2024
Lexicon Announces Exclusive Licensing Agreeme...
Benzinga Newsdesk
Wednesday, October 09, 2024
Viatris Announced Topline Results From Its Ph...
Benzinga Newsdesk
Monday, October 07, 2024
Novo Nordisk Settles US Patent Dispute With V...
Benzinga Newsdesk
Monday, September 30, 2024
Viatris Launches Viagra ODF in Canada, A New ...
Benzinga Newsdesk
Tuesday, September 24, 2024
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Vandana Singh
Friday, September 20, 2024
EXCLUSIVE: Options Expert Warns Of 'Terrible Week' After Friday's Triple Witching
Piero Cingari
Wednesday, September 18, 2024
Viatris Announces Pricing Terms Of $575M Maxi...
Benzinga Newsdesk
Tuesday, September 10, 2024
Viatris Announces The Pricing Terms Of Cash T...
Benzinga Newsdesk
Friday, September 06, 2024
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
Vandana Singh
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
Vandana Singh
Friday, August 23, 2024
Viatris Says Late-breaking Oral Presentation ...
Benzinga Newsdesk
Thursday, August 15, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
Thursday, August 08, 2024
US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs
Vandana Singh
Viatris shares are trading higher after the c...
Benzinga Newsdesk
Viatris Expects 2024 Adjusted EPS Of $2.58-$2...
Benzinga Newsdesk
Viatris Expects 2024 Sales Of $14.6B-$15.1B V...
Benzinga Newsdesk
Viatris Q2 2024 Adj. EPS $0.69 Beats $0.68 Es...
Benzinga Newsdesk
Tuesday, August 06, 2024
Theravance Q2 Loss Wider Than Expected, Revenues Rise Y/Y
Zacks
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
Vandana Singh
Sunday, July 21, 2024
Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?
Lekha Gupta
Friday, July 19, 2024
Jefferies Reinstates Buy on Viatris, Announce...
Benzinga Newsdesk
Friday, July 05, 2024
Reported Thursday, Calliditas Therapeutics An...
Benzinga Newsdesk
Wednesday, July 03, 2024
Viatris Completes All Previously Announced Di...
Benzinga Newsdesk
Tuesday, July 02, 2024
Viatris Announced That The Antitrust Division...
Benzinga Newsdesk
Monday, May 27, 2024
Peering Into Viatris's Recent Short Interest
Benzinga Insights
Thursday, May 23, 2024
Viatris shares are trading lower on continued...
Benzinga Newsdesk
Thursday, May 09, 2024
Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast
Vandana Singh
Stocks Rebound As Rising Jobless Claims Sustain Rate-Cut Hopes, Dollar Falls, Gold Rallies: What's Driving Markets Thursday?
Piero Cingari
Viatris shares are trading lower after the co...
Benzinga Newsdesk
Viatris Expects 2024 Adjusted EPS Of $2.66-$2...
Benzinga Newsdesk
Viatris Expects 2024 Revenues Of $14.98B-$15....
Benzinga Newsdesk
Viatris Q1 2024 GAAP EPS $0.67, Inline, Sales...
Benzinga Newsdesk
Wednesday, May 01, 2024
Viatris Launched Unmind As Part Of Its Global...
Benzinga Newsdesk
Monday, April 15, 2024
Viatris Reports Launch Of First Bioequivalent...
Benzinga Newsdesk
Friday, April 05, 2024
Theramex Says Currently Considering CMA's Dec...
Benzinga Newsdesk
Monday, April 01, 2024
Ocuphire Announces the US Commercial Launch o...
Benzinga Newsdesk
Viatris Announced The U.S. Commercial Launch ...
Benzinga Newsdesk
Thursday, March 28, 2024
Piper Sandler Reiterates Neutral on Viatris, ...
Benzinga Newsdesk
Friday, March 15, 2024
Looking Into Viatris's Recent Short Interest
Benzinga Insights
Monday, March 11, 2024
Viatris shares are trading lower after the co...
Benzinga Newsdesk
Earlier On Monday, Viatris' Mapi Pharma Recei...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch